Sino-American trade talks make positive progress over 3 consecutive days.

Joseph Corr

2019-01-17 10:41:00 Thu ET

Sino-American trade talks make positive progress over 3 consecutive days as S&P 500 and global stock market indices post 3-day win streaks. Asian and European stock markets reap sharp gains primarily due to cautious optimism over the results of complete trade negotiations between China and America. In this new light, stock market analysts view these trade talks as serious and productive because these talks extend to the third day with some concrete trade war resolution. The 3-day trade negotiations between mid-level Sino-U.S. senior reps end on a positive note and also help clear the way for subsequent higher-level trade talks. All these joint effects aim to avert any further major escalation of the Sino-American trade war in early-March 2019.

The Xi administration pledges to buy more U.S. goods and also seeks to improve the best practices on Chinese intellectual property protection. The trade talks can help reduce the Sino-American trade deficit by a substantial dollar amount. In turn, the Trump team emphasizes the clear intention to ensure Chinese compliance with *continual verification and effective enforcement*. Thus, the Trump administration continues to restrict Chinese investments in critical technology transfers from U.S. tech titans such as Apple, Amazon, Google, Intel, Microsoft, and Qualcomm etc.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Berkeley tax economists Gabriel Zucman and Emmanuel Saez find fresh insights into wealth inequality in America.

Jacob Miramar

2019-06-27 10:39:00 Thursday ET

Berkeley tax economists Gabriel Zucman and Emmanuel Saez find fresh insights into wealth inequality in America.

Berkeley tax economists Gabriel Zucman and Emmanuel Saez find fresh insights into wealth inequality in America. Their latest estimates show that the top 0.1

+See More

Netflix has an unsustainable business model in the meantime.

Becky Berkman

2019-05-02 13:30:00 Thursday ET

Netflix has an unsustainable business model in the meantime.

Netflix has an unsustainable business model in the meantime. Netflix maintains a small premium membership fee of $9-$14 per month for its unique collection

+See More

We assess almost all aspects of the current global race toward artificial general intelligence (AGI) between both the U.S. and China.

Monica McNeil

2027-10-31 00:00:00 Sunday ET

We assess almost all aspects of the current global race toward artificial general intelligence (AGI) between both the U.S. and China.

In the technological race between the U.S. and China, America leads in some strategic sectors from AI large language models (LLM), graphics processing units

+See More

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

John Fourier

2024-05-05 10:31:00 Sunday ET

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its

+See More

The Economist delves into the modern perils of tech titans such as Apple, Amazon, Facebook, and Google.

Jacob Miramar

2018-01-12 07:37:00 Friday ET

The Economist delves into the modern perils of tech titans such as Apple, Amazon, Facebook, and Google.

The Economist delves into the modern perils of tech titans such as Apple, Amazon, Facebook, and Google. These key tech titans often receive plaudits for mak

+See More

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an

+See More